Physiopathology of splanchnic vasodilation in portal hypertension. - Wikidata - wikimedia - TriplyDB

Physiopathology of splanchnic vasodilation in portal hypertension.

Physiopathology of splanchnic vasodilation in portal hypertension.

http://www.wikidata.org/entity/Q37821307

about

Hepatosplanchnic circulation in cirrhosis and sepsis Cardiovascular dysfunction in patients with liver cirrhosis Normothermic perfusion in the assessment and preservation of declined livers prior to transplantation: hyperoxia and vasoplegia - important lessons from the first 12 cases.A half century (1961-2011) of applying microsurgery to experimental liver research A Novel Predictor of Posttransplant Portal Hypertension in Adult-To-Adult Living Donor Liver Transplantation: Increased Estimated Spleen/Graft Volume Ratio.Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools.Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites.New cellular and molecular targets for the treatment of portal hypertension.Portopulmonary hypertension in children: a rare but potentially lethal and under-recognized disease.Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys.Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage.A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.Blood loss, predictors of bleeding, transfusion practice and strategies of blood cell salvaging during liver transplantation.Strain of experimental animals and modulation of nitric oxide pathway: their influence on development of renal failure in an experimental model of hepatorenal syndrome.Effect of nitric oxide pathway regulation on water/sodium balance and renal function in a rodent model of acute liver and renal failure.Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension.Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension.The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats Gut-Brain Chemokine Changes in Portal Hypertensive Rats INVOLVEMENT OF CATECHOLAMINES IN THE MYOCARDIUM OF RATS SUBMITTED TO EXPERIMENTAL MODEL OF PORTAL HYPERTENSION

P2860

Q26864350-742D13CD-0130-4051-97F8-0F0708284787 Q27010592-36C95D79-BDF5-4360-9379-5DC643ED4BC9 Q30490781-DB96C00A-1B59-4C76-9B3F-B2FEE5AEB151 Q36131247-1A17454F-064C-45B5-B588-3718C06D766B Q37432592-0456AFA3-A375-4499-9165-23ED5263635A Q37917815-2638B72F-7742-45CD-A213-74A7EB9C7748 Q38049065-84538703-565F-4A3D-AC4C-32C1C7C9E92D Q38383418-3991D291-75E2-4A98-92BB-0D3E5B3DCEAE Q38658198-DB1CD90F-4D7C-49C9-9D82-9EED0BB1764B Q39966848-F3DBCB34-0B91-4AAC-BB46-3B7453740D8B Q41785704-C4E6CD36-1350-4608-8983-7F28CB4DD277 Q41848559-1E62D6BD-DD3A-4AC3-9811-754EDD18E568 Q41938260-C78387B6-1B6D-40BE-A3FB-286F372D5989 Q42214939-B570B356-A0D3-4A26-8F21-2B08BBC94A20 Q42930716-AEA4F8DD-94B3-439A-BED6-8F7CB81F91EF Q43245098-DCC663B6-2DBC-42AD-A55A-CCF92BAF970F Q48682958-7520FF3D-05DA-422D-AB80-15F2F01069FA Q57147093-373983F7-E46F-47CB-981A-FD5DD3F543DD Q58455105-851E96B2-BA98-423A-9850-3751128CF28B Q58774276-CE855CBA-F6CD-417B-8E77-6DA4547A8EB3

P2860

Physiopathology of splanchnic vasodilation in portal hypertension.

http://www.wikidata.org/entity/Q37821307

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Physiopathology of splanchnic vasodilation in portal hypertension.

@en

Physiopathology of splanchnic vasodilation in portal hypertension.

@nl

type

label

Physiopathology of splanchnic vasodilation in portal hypertension.

@en

Physiopathology of splanchnic vasodilation in portal hypertension.

@nl

prefLabel

Physiopathology of splanchnic vasodilation in portal hypertension.

@en

Physiopathology of splanchnic vasodilation in portal hypertension.

@nl

P1433

Q37821307-8AF7750E-C9A0-474F-9B52-ABCC1F9AD91E

P1476

Q37821307-6458DE7A-9644-492E-B03D-65BA85A1FF9C

P2093

Q37821307-51FD4318-2BB2-492D-9AB9-0BAAE9923C7C

Q37821307-7DCBA9CE-4252-4EA5-914B-3A3A0C2D3EB8

Q37821307-A8ECC791-853B-421E-B9A7-8E83D56533DC

Q37821307-AE27D38A-AAC1-4478-8F0B-6E527A527E70

Q37821307-F70DDD16-5C3F-4402-81AA-36AF4A423905

P2860

Q37821307-00A01701-B484-46CA-A35B-97DDA7B86FEF

Q37821307-023CB57D-A665-4EA5-BE02-174AFB3B3215

Q37821307-03EA4FE1-0C6F-4817-9ACB-A063EE23F32D

Q37821307-06D09A29-192E-4261-ADF4-835C0F53F5C7

Q37821307-0A1F9C6F-9B85-4BB7-AC4F-1FB8A052FE1C

Q37821307-0A73246B-9D38-49AA-BFE8-1CEA16F5CA96

Q37821307-0B75D0EF-E03A-4D12-B7E4-11A3FEAAFECF

Q37821307-0DA20BCE-6068-42C0-A1D0-B2A3F4E589C9

Q37821307-0DDB224F-E7D6-4424-A820-A253F644E50C

Q37821307-0ED7E45C-A3FE-41A6-9458-E38D6F46B406

P304

Q37821307-3767CBAA-E451-416D-AAE7-22622DFCC7A7

P31

Q37821307-9d999286-cff1-4277-99a4-aea607365bd1

Q37821307-DF8756C9-08CA-415C-8899-6E91FB90EA4E

P356

Q37821307-327DEFBA-5165-4148-827A-5EE5478F75F9

P433

Q37821307-8533A5EA-F89D-4DD9-A0B8-F1821865847C

P478

Q37821307-C521ED2E-946C-48DC-9BBC-FB31B7E99785

P577

Q37821307-6BA2EBCA-855F-452C-89C1-DBE6E5920FED

P5875

Q37821307-781946A9-3553-4771-9AE7-E27D52D0CD89

P698

Q37821307-AD8A7AE8-CA41-4E33-872B-31D45E0B02A3

P921

Q37821307-45A1B79B-92B5-40B6-8E00-F88DDB778E4C

P932

Q37821307-9BBC46B3-D823-4371-86EE-830F196D5ADC

P356

P1433

World journal of hepatology

P1476

Physiopathology of splanchnic vasodilation in portal hypertension.

@en

P2093

Imma Raurell

http://www.w3.org/2001/XMLSchema#string

Joan Genescà

http://www.w3.org/2001/XMLSchema#string

Mar Coll

http://www.w3.org/2001/XMLSchema#string

María Martell

http://www.w3.org/2001/XMLSchema#string

Nahia Ezkurdia

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases

The Akt kinase signals directly to endothelial nitric oxide synthase

Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension

Nitric oxide as a secretory product of mammalian cells

Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling

Disordered central cardiovascular regulation in portal hypertensive and cirrhotic rats.

Subcellular targeting and differential S-nitrosylation of endothelial nitric-oxide synthase.

G-protein coupled receptor kinases as modulators of G-protein signalling.

P304

208-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4254/WJH.V2.I6.208

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49686032

http://www.w3.org/2001/XMLSchema#string

P698

21160999

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

2999290

http://www.w3.org/2001/XMLSchema#string